Going viral with cancer immunotherapy.

Area of Science:

• Immunology
• Virology
• Oncology

Background:

• Clinical data demonstrate the immune system's potential to eradicate advanced cancers.
• Oncolytic viruses (OVs), initially designed for tumor lysis, now show capacity to induce systemic antitumour immunity.
• Tumor cell signaling pathways that promote cancer growth also support OV replication.

Purpose of the Study:

• To highlight the role of oncolytic viruses in enhancing antitumour immune responses.
• To explore the potential of engineered OVs with immune-stimulating cargo.
• To discuss the convergence of OV therapy with other immunotherapies for improved cancer treatment.

Main Methods:

• Review of recent clinical data on oncolytic virus therapy.
• Analysis of OV mechanisms in activating systemic antitumour immunity.
• Exploration of OV engineering for enhanced immune stimulation and targeted delivery.

Main Results:

• Oncolytic viruses induce immunogenic tumour cell death and selective tumour targeting.
• Engineered OVs can express immune-stimulating cargo, amplifying antitumour effects.
• OV therapy shows promise in conjunction with tumour antigen vaccination, immune checkpoint inhibitors, and adoptive cell therapy.

Conclusions:

• Oncolytic viruses are potent agents for enhancing systemic antitumour immune responses.
• The strategic combination of OV therapy with other immunotherapies represents a promising new generation of multimodal cancer therapeutics.
• This integrated approach holds significant potential to improve clinical outcomes for cancer patients.